Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Donald F Gleason in 1966 created a unique grading system for prostatic carcinoma based solely on the architectural pattern of the tumor. 1, 2 Another innovative aspect of this system was, rather than ...

- Results showed 100% sensitivity and reduced time to diagnosis by an estimated 65.5%, with potential to improve pathologists’ workflow in a real-world environment -Brazil-based Grupo Oncoclinicas is ...

Does a Custom Electronic Health Record Alert System Improve Physician Compliance With National Quality Measures for Palliative Bone Metastasis Radiotherapy? This approach aims to reduce delays in data ...

The US Food and Drug Administration (FDA) has authorized marketing of artificial intelligence (AI) software to help pathologists detect prostate cancer. The program, called Paige Prostate, is the ...

Alphabet’s life sciences arm, Verily, is partnering with the digital pathology platform Lumea to improve the objectivity and efficiency of prostate cancer diagnosis, prognosis and therapy selection.

Just Enough Palliation: Radiation Dose and Outcome in Patients With Non–Small-Cell Lung Cancer A prospectively designed algorithm was applied retrospectively to a cohort of 758 patients with ...

Prostate cancers remain localized in the majority of cases, giving affected individuals a good chance of survival. However, about 20% of patients develop incurable metastatic prostate cancer, ...

Each 20-unit increment in GPS was associated with a more than 2-fold increased likelihood of recurrence. Genomic Prostate Score (GPS), a 17-gene molecular assay, strongly and independently predicts ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Novel risk stratification tool advances the frontier of precision oncology by providing access to insights informing critical on-the-ground treatment decisions Artera, the developer of multimodal ...